On November 2, 2015 SRI International reported that it has been awarded a contract of up to $9 million to provide preclinical development services to the National Cancer Institute (NCI) PREVENT Cancer Program (PCP) (Press release, SRI International, NOV 2, 2015, View Source [SID:1234507884]). Under the contract, SRI will provide scientific expertise, modern testing and support facilities, and analytical instrumentation to conduct a wide variety of preclinical pharmacology and toxicology studies to evaluate potential cancer prevention drugs. Schedule your 30 min Free 1stOncology Demo! The PREVENT Cancer Drug Development Program is an NCI-supported pipeline to bring new cancer preventing interventions and biomarkers through preclinical development towards clinical trials. PREVENT enables milestone-driven progression of novel cancer preventive chemical or biological agents and biomarkers from the laboratory bench towards proof-of-principle clinical testing and registration or validation.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We welcome the opportunity to provide preclinical toxicology and pharmacology services to support the NCI’s PREVENT program," said Toufan Parman, Ph.D., D.A.B.T, director, General Toxicology, SRI Biosciences, and principal investigator for the NCI contract. "We’ve provided such services to the NCI for the past 23 years, and look forward to continue applying our expertise to this important work."
The current contract calls for SRI to deliver high-quality laboratory data to support NCI-PCP’s efforts to develop promising therapeutic candidates such as vaccines and cancer chemopreventive agents that will inhibit, delay or reverse manifestations of cancer. SRI will be responsible for managing therapeutic candidates from conception to submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. SRI has broad experience with similar studies for NCI and for many other divisions of the National Institutes of Health, as well as for private sponsors.